IRCT20180620040164N44
Not yet recruiting
未知
Comparative bioequivalence study of Escitalopram 20 mg F.C. Tablet of Karen. and Cipralex of Lundbeck Limited as reference in 24 healthy male under fasting.
Karen Pharma and Food Supplement Co.0 sites24 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Karen Pharma and Food Supplement Co.
- Enrollment
- 24
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy subjects (male) between 18 – 40 years of age and Body Mass Index (BMI) between 18\.5 and 30 (inclusive), calculated as kg/m2\.
- •Sitting blood pressure less than 100/ 60 mm Hg;
- •Subjects with no significant diseases or clinically significant abnormal findings during screening, medical history, clinical examination and laboratory evaluations.
- •Subjects with normal ECG and vital signs.
- •Subjects who agree with patient consent form.
Exclusion Criteria
- •Known hypersensitivity or idiosyncratic reaction to Escitalopram or inactive Allergy to any medication, substance, or food.
- •History of cardiovascular, kidney, hepatic, muscular, metabolic, gastrointestinal (including constipation), neurologic, endocrine, any kind of anemia, asthma, and mental disease.
- •Muscular trauma 21 days before the beginning of the study.
- •Administration of any medication in the 14 days or 5 half\-lives (whatever longer) previous to the beginning of the study and might need drug intake during study period.
- •Use of any medication known to alter hepatic enzyme activity within 28 days prior to the initial dose of study medication.
- •Subjects who have a history of alcohol or substance abuse within the last 5 years.
- •Heavy drinker of alcohol, grapefruit juice or caffeinated drinks or who are on special diet (such as vegetarians) or do exertional physical activity.
- •A history of difficulty with donating blood or donation of more than 450 ml blood within 60 days prior to the start of the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Comparative in vivo evaluation of 2 Escitalopram 20 mg F.C. Tablet formulations.Mood disorder due to known physiological condition with major depressive-like episode.Mood disorder due to known physiological condition with major depressive-like episodeF06.32IRCT20180620040164N39Actover Pharmaceutical Co.24
Completed
Phase 4
Bioequivalence Study of 10 mg Escitalopram Oxalate Film Coated Tablets in Healthy VolunteersHealthy volunteersTCTR20161025003Medifive Pharma Co., Ltd.24
Completed
Not Applicable
Bioeqivalence study of escitalopram 10 mg tabletA crossover bioequivalence study in 24 healthy volunteers.IRCT20220209053979N6Pars Darou Company24
Recruiting
Phase 3
Treatment of depressive symptoms in patients with heart failureDepression.Major depressive disorder, single episode, mildF32.0IRCT20190525043700N5Babol University of Medical Sciences80
Completed
Phase 2
Evaluation of the effect of Escitalopram versus placebo trial on changing the neuroticismeuroticism or neuroticism.Post-traumatic stress disorder, acuteF43.11IRCT20211208053331N1Ahvaz University of Medical Sciences172